Is Liraglutide FDA approved?
This profile records Liraglutide as FDA approved.
MORE CONTEXT ›
Approval can be specific to a formulation, indication, and prescribing context, so review the regulatory and source details on this page.
Metabolic CATEGORY
Liraglutide
THE DAILY
Saxenda, Victoza
Liraglutide is a GLP-1 receptor agonist that works similarly to Semaglutide but requires daily injections instead of weekly. It helps control appetite, slows digestion, and improves blood sugar regulation. Originally developed for diabetes (Victoza), a higher dose version (Saxenda) was approved specifically for weight management. It's a proven option for those who prefer more frequent, smaller doses.
Liraglutide
Liraglutide
Liraglutide
Liraglutide Evidence Snapshot
How these guides are reviewed
REGULATORY STATUS
FDA-approved uses exist
DOSING GUIDANCE
Reviewed by our clinical team
LINKED EVIDENCE
Sources pending
CONTENT UPDATED
Jul 15, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
Quick Answers About Liraglutide
What dose does The Peptide App Clinical Team recommend for Liraglutide?
Dose: 0.6mg to 3mg daily (gradual increase).
MORE CONTEXT ›
Schedule: daily. Cycle: Continuous use with medical supervision. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
What research supports this Liraglutide guide?
No linked research sources are currently available on this guide.
MORE CONTEXT ›
Treat the profile as provisional until supporting sources are published.
People seeking FDA-approved weight loss medication
Type 2 diabetics needing blood sugar control
Those who prefer daily dosing over weekly
Individuals starting GLP-1 therapy
Liraglutide Research
Live research temporarily unavailableThe live research feed did not return papers for this page. The curated references below remain available for crawlable source context.